GSK: towards simpler HIV care
(CercleFinance.com) - ViiV Healthcare, a global HIV company that is majority-owned by GlaxoSmithKline (GSK), on Saturday presented data from a Phase IIIb study evaluating the long-acting regimen of cabotegravir and rilpivirine for the treatment of HIV.
The results from week 96 show the efficacy of both the monthly administration of the treatment and administration every 2 months over the long term in patients with an undetectable HIV burden.
"This regimen can enable people living with HIV to reduce the days they receive treatment from 365 to 12 or 6 per year, representing a paradigm shift in their experience of HIV treatment," says Hans Jäeger, MD, former medical director of MVZ Karlsplatz, Centre for HIV Research and Clinical Care, Munich.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
The results from week 96 show the efficacy of both the monthly administration of the treatment and administration every 2 months over the long term in patients with an undetectable HIV burden.
"This regimen can enable people living with HIV to reduce the days they receive treatment from 365 to 12 or 6 per year, representing a paradigm shift in their experience of HIV treatment," says Hans Jäeger, MD, former medical director of MVZ Karlsplatz, Centre for HIV Research and Clinical Care, Munich.
Copyright (c) 2021 CercleFinance.com. All rights reserved.